Boardroom Alpha
Boardroom Alpha
SNOA · Additional Proxy Materials (DEFA14A) · Filed June 24, 2026

Sonoma Pharmaceuticals Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
June 24, 2026
Ticker
SNOA
Accession
0001683168-26-005092
Boardroom Alpha · Filing insights

Sonoma adjourns the special meeting to July 22, 2026; board urges voting FOR Nevada reincorporation and FOR adjournment to secure more proxies.

About Sonoma Pharmaceuticals Inc
Market cap
$7M
1Y TSR
−69.1%
3Y TSR
−59.2%
Board grade
C-
Sector
Healthcare
CEO
Amy Moss Trombly
Last annual meeting: Sep 16, 2026 · View full Sonoma Pharmaceuticals Inc profile →

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

 

Check appropriate box:

 

Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Pursuant §240.14a-12

 

SONOMA PHARMACEUTICALS, INC.
(Name of Registrant as Specified in its Charter)
 
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

No fee required.
   
Fee computed based on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
     
  1) Title of each class of securities to which transaction applies:
     
  2) Aggregate number of securities to which transaction applies:
     
  3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
     
  4) Proposed maximum aggregate value of transaction:
     
  5) Total fee paid:
     
   
Fee paid previously with preliminary materials.
   
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
     
  1) Amount Previously Paid:
     
  2) Form, Schedule or Registration Statement No.:
     
  3) Filing Party:
     
  4) Date Filed:
     

 

 

 

   

 

 

 

 

NOTICE OF ADJOURNMENT OF SPECIAL MEETING

 

PLEASE VOTE YOUR PROXY TODAY

 

 

June 24, 2026

 

Dear Stockholder:

 

You recently received proxy materials relating the Special Meeting of Stockholders of Sonoma Pharmaceuticals, Inc. (the “Company”). This important notice is to inform you that the Special Meeting has been adjourned until July 22, 2026 at 2:00 p.m., local time, to allow stockholders additional time to exercise their voting rights by submitting their voting instructions. The adjourned meeting will be held at the Company’s principal executive offices located at 5445 Conestoga Court, Suite 150, Boulder, CO 80301.

 

This letter was sent to you because you held shares of the Company on the record date and we have not yet received your vote. In order to hold the special meeting, we need to have a quorum for the special meeting (at least a majority of the outstanding shares present and voting at the meeting). Your vote is extremely important, no matter how many shares you hold or how you choose to vote. PLEASE VOTE YOUR SHARES TODAY.

 

For the reasons set forth in the proxy statement, dated May 5, 2026, the Board of Directors recommends that you vote “FOR” the Company’s reincorporation to the State of Nevada and “FOR” approval of adjournment of the Special Meeting to establish a quorum or to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting. Please vote via the internet or phone as soon as possible or alternatively, please sign, date, and return the enclosed proxy card.

 

On behalf of your Board of Directors, thank you for your cooperation and continued support.

 

 

Sincerely,

 

 

Amy Trombly

Chief Executive Officer

 

 

 

 

 

 2 

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Sonoma Pharmaceuticals Inc (SNOA)

Reference

Frequently asked questions

When did Sonoma Pharmaceuticals Inc file this DEFA14A?
Sonoma Pharmaceuticals Inc (SNOA) filed this Additional Proxy Materials (DEFA14A) with the SEC on June 24, 2026. The accession number assigned by EDGAR is 0001683168-26-005092.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Sonoma adjourns the special meeting to July 22, 2026; board urges voting FOR Nevada reincorporation and FOR adjournment to secure more proxies. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Sonoma Pharmaceuticals Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Sonoma Pharmaceuticals Inc has filed under CIK 1367083, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer